The Combination of <i>p53</i> Mutation and <i>neu/erb</i>B-2 Amplification Is Associated With Poor Survival in Node-Negative Breast Cancer

Abstract

Evaluation of tumors for p53 mutations may be beneficial to identify women at higher risk of disease recurrence and death when the tumor has neu/erbB-2 amplification, but in the absence of neu/erbB-2 amplification, the presence of p53 mutation may not provide additional independent prognostic information.